– Primary endpoint of asthma worsening not met in LEDA Study, however consistent numeric reductions ranging from 32-35% observed across all three GB001 groups – – Statistically significant improvements in key secondary endpoint of time to first asthma worsening of 28% and 30% observed for 20 mg and 60 mg […]
Bio
Regardless of Period 2 Failure, Gossamer Bio Sees a Route for Drug in Asthma
Xconomy San Diego — Gossamer Bio’s direct drug, an experimental cure for asthma and allergies, has unsuccessful in two mid-stage clinical trials but the biotech sees adequate in the information to go after further more advancement in a severe type of asthma and it wants to chat with regulators about […]